At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 447 enrolled
Drug / intervention
Vortioxetine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction
In Brief
A Phase 3 clinical trial evaluating Vortioxetine, Escitalopram, and 1 other intervention for Treatment Outcome. Completed, enrolled 447 participants across 62 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Outcome
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionDec 2013
TodayJul 2026
First PostedJun 2, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.1 years ago
Interventions
Vortioxetinedrug
Vortioxetine tablets
Escitalopramdrug
Escitalopram tablets
Placebodrug
Vortioxetine Placebo-matching capsules